Moderna (MRNA) Touches 52-Week High on Strong Clinical Results

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one of the worst performers on Wednesday.

Moderna surged to a new 52-week high of $50 on Wednesday, a 16 percent jump, as investors took heart from the strong results of its clinical study for Intismeran Autogene in Combination With KEYTRUDA(R) in patients with high-risk melanoma.

At market close, the stock pared gains to end the session just up by 15.84 percent at $49.81 apiece.

In an updated report, Moderna Inc. (NASDAQ:MRNA) said that the median five-year follow-up data from the Phase 2b study showed that the therapy reduced death risks of patients by 49 percent as compared to Keytruda alone.

Moderna Inc. (NASDAQ:MRNA) and Merck plan to present further data from follow up analyses of primary and secondary endpoints at an upcoming medical meeting.

In collaboration with Merck, the Phase 3 clinical trial for adjuvant melanoma (INTerpath-001, NCT05933577) is fully enrolled.

Two non-small cell lung cancer (NSCLC) Phase 3 studies—evaluating adjuvant treatment in patients with completely resected NSCLC and adjuvant treatment for patients with resectable NSCLC after receiving neoadjuvant KEYTRUDA plus platinum-based chemotherapy—are enrolling.

“The randomized Phase 2 study for adjuvant renal cell carcinoma is fully enrolled. Randomized Phase 2 studies for patients with resected muscle invasive and resected non-muscle invasive bladder cancer are enrolling, a Phase 2 study of first-line treatment for patients with metastatic melanoma and a Phase 2 study of first-line treatment for patients with metastatic squamous NSCLC are also enrolling,” Moderna Inc. (NASDAQ:MRNA) said.

While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.